Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

DeFinium Therapeutics Inc (DFTX)

DeFinium Therapeutics Inc (DFTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,711,101
  • Shares Outstanding, K 98,509
  • Annual Sales, $ 0 K
  • Annual Income, $ -108,680 K
  • EBIT $ -151 M
  • EBITDA $ -150 M
  • 60-Month Beta 2.57
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.94

Options Overview Details

View History
  • Implied Volatility 99.26% (+2.26%)
  • Historical Volatility 63.99%
  • IV Percentile 89%
  • IV Rank 96.02%
  • IV High 100.49% on 01/28/26
  • IV Low 69.57% on 01/22/26
  • Expected Move (DTE 9) 1.32 (7.58%)
  • Put/Call Vol Ratio 0.15
  • Today's Volume 567
  • Volume Avg (30-Day) 2,157
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 57,781
  • Open Int (30-Day) 52,494
  • Expected Range 16.05 to 18.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.45
  • Number of Estimates 4
  • High Estimate -0.37
  • Low Estimate -0.54
  • Prior Year -0.41
  • Growth Rate Est. (year over year) -9.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.88 +34.84%
on 01/12/26
18.70 -7.11%
on 02/02/26
+3.53 (+25.51%)
since 01/09/26
3-Month
10.46 +65.99%
on 11/21/25
18.70 -7.11%
on 02/02/26
+5.62 (+47.83%)
since 11/10/25
52-Week
4.70 +269.57%
on 04/09/25
18.70 -7.11%
on 02/02/26
+9.19 (+112.35%)
since 02/10/25

Most Recent Stories

More News
Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of...

DFTX : 17.37 (+0.12%)
Definium Therapeutics Appoints Roger Adsett to Board of Directors

Seasoned biopharmaceutical leader brings deep commercial, operational, and launch expertise to support Definium’s next phase of growth

DFTX : 17.37 (+0.12%)
Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of...

DFTX : 17.37 (+0.12%)
Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care

Rerouting Minds is designed to increase understanding of pharmaceutical lysergide (LSD) and the role of rigorous psychedelic research in addressing unmet needs in severe mental health disorders...

DFTX : 17.37 (+0.12%)
Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026

Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) (the "Company" or “Definium") is updating its previous announcement that the Company’s Common Shares would begin trading on Nasdaq...

DFTX : 17.37 (+0.12%)
MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026

Topline Data from Three Phase 3 Studies Evaluating DT120 Orally Disintegrating Tablet (ODT) for GAD and MDD Expected in 2026: Voyage in 2Q, Panorama in 2H, and Emerge Mid-Year Company Presenting...

DFTX : 17.37 (+0.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Definium Therapeutics, Inc. is developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Definium Therapeutics Inc., formerly known as Mind Medicine Inc., is based in NEW YORK....

See More

Key Turning Points

3rd Resistance Point 18.62
2nd Resistance Point 18.21
1st Resistance Point 17.79
Last Price 17.37
1st Support Level 16.96
2nd Support Level 16.55
3rd Support Level 16.13

See More

52-Week High 18.70
Last Price 17.37
Fibonacci 61.8% 13.35
Fibonacci 50% 11.70
Fibonacci 38.2% 10.05
52-Week Low 4.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar